α-2-HS-糖蛋白对聚乙二醇干扰素alfa-2b治疗慢性乙型肝炎患者e抗原血清转换预测作用的研究  

α-2-HS-glycoprotein:A Potential Marker Predicting Chronic Hepatitis B Patients E Seroconversion During Pegylated Interferon Alfa-2b By 4 week Up-regulated

作　　者：马慧[1] 王江华[1] 郭芳[1] 魏来[1] 

机构地区：[1]北京大学人民医院北京大学肝病研究所,北京100044

出　　处：《中国科学：生命科学》2010年第9期859-867,共9页Scientia Sinica(Vitae)

基　　金：国家重点基础研究发展计划(批准号:2005CB522902,2007CB512900);国家高技术研究发展计划(批准号:2006AA02A410);国家自然科学基金(批准号:30901256);北京市自然科学基金(批准号:7102153);国家科技重大专项(批准号:2008ZX10002-012,2008ZX10002-013);北京大学人民医院研究发展基金(批准号:RDC2009-13)资助项目

摘　　要：利用干扰素治疗慢性乙型肝炎仅在约1/3的患者中取得了满意的治疗效果.采用基于双向电泳的血清蛋白质组学技术,寻找慢性乙型肝炎患者干扰素治疗时发生e抗原血清学转换的预测标志物.对发生/未发生血清学转换组的患者基线和治疗24周血清进行差异蛋白的筛选和鉴定,并对筛选得到的α-2-HS-糖蛋白在训练组和验证组患者个体中进行了基线和第4周的进一步验证实验.结果发现,α-2-HS-糖蛋白从治疗基线至治疗第4周的变化趋势对慢性乙型肝炎患者干扰素alfa-2b治疗过程中e抗原血清学转换具有预测意义.The efficacy of interferon （IFN） is limited in about a third of the treated chronic hepatitis B （CHB） patients. Here, we used 2-DE based proteomic strategies to identify potential serum markers predicting hepatitis B e antigen （HBeAg） seroconversion in these patients during IFN therapy. Two groups of patients were enrolled as training and validation groups. In the training group, 2-DE experiments and following identification of altered proteins showed that α-2-HS-glycoprotein, leucine-rich α-2-glycoprotein, and haptoglobin were significantly up-regulated as compared to the baseline levels in the HBeAg seroconversion group, while apolipoprotein C-III precursor, leucine-rich α-2-glycoprotein, and a-albumin were down-regulated in the non-seroconversion group. For patients with HBeAg seroconversion in the training group, the results of the western blot analysis showed that the α-2-HS-glycoprotein levels in 75% of the patients were significantly up-regulated at the end of treatment as compared to the baseline levels. Subsequent validation experiments in the validation group showed that the ct-2-HS-glycoprotein levels significantly increased at week 4 in 83.33% of the patients in the HBeAg seroconversion group. Dynamic changes in the serum level of α-2-HS-glycoprotein may be a potential early marker for predicting HBeAg seroconversion during IFN treatment for chronic hepatitis B.

关 键 词：α-2-HS-糖蛋白聚乙二醇干扰素alfa-2b慢性乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]